Pfizer Inc And Biontech Se
- All
- News
- Videos
-
What To Know About COVID-19 Vaccine For US Children
The US Food and Drug Administration is considering authorizing a COVID-19 vaccine for children aged 5 to 11. The vaccine from Pfizer Inc and BioNTech SE has been available in the United States to kids aged 12 to 15 since May.
-
Pfizer Submits Initial Data For Covid Vaccine Booster Authorization
Pfizer Inc and its German partner BioNTech SE have submitted to U.S. regulators the initial data from an early-stage trial toward seeking authorization of a booster dose of their COVID-19 vaccine, the drugmakers said on Monday.
-
Pfizer, Moderna Vaccines Highly Effective Even After 1st Shot: US Study
COVID-19 vaccines developed by Pfizer Inc with BioNTech SE and Moderna Inc reduced the risk of infection by 80 per cent two weeks or more after the first of two shots, according to data from a real-world study of vaccinated US healthcare personnel and first responders released on Monday.
-
Pfizer, BioNTech Launch COVID-19 Vaccine Trial In Children Under 12
Pfizer Inc and German partner BioNTech SE began testing their COVID-19 vaccine in children under 12, with hopes of expanding vaccination to that age range by early 2022, the U.S. drugmaker said on Thursday.
-
Pfizer-Biontech Testing Booster Of Their COVID-19 Vaccine In New Trial
Pfizer Inc and BioNTech SE said on Thursday they are testing a third dose of their COVID-19 vaccine to better understand the immune response against new variants of the virus.
-
South African Virus Variant Could Significantly Reduce Vaccine Protection: Pfizer
A laboratory study suggests that the South African variant of the coronavirus may reduce antibody protection from the Pfizer Inc/BioNTech SE vaccine by two-thirds, and it is not clear if the shot will be effective against the mutation, the companies said on Wednesday.
-
Pfizer And BioNtech To Offer Covid Vaccine To Volunteers Who Got Placebo
Pfizer Inc and its partner BioNTech Se plan to give volunteers who received a placebo in its COVID-19 vaccine trial an option to receive a first dose of the vaccine by March 1, 2021, while staying within the study.
-
How Moderna's COVID-19 Vaccine Compares To That Of Pfizer's
US regulators authorized Moderna Inc's COVID-19 vaccine for emergency use on Friday, a week after granting the first US authorization to Pfizer Inc and BioNTech SE's coronavirus shot.
-
US Drug Regulator Investigating 5 Allergic Reactions After Pfizer Shot
The US Food and Drug Administration is investigating around five allergic reactions that happened after people were administered Pfizer Inc and BioNTech SE's COVID-19 vaccine in the United States this week, a top FDA official said late on Friday.
-
BioNTech CEO Reveals "Biggest Challenge" After Covid Vaccine Gets US Nod
The chief executive of Germany's BioNTech SE said the biggest challenge facing it and partner Pfizer Inc now that their COVID-19 vaccine is authorized for use in the United States will be to scale up manufacturing to meet huge demand.
-
No Allergic Reactions Recorded During Covid Vaccine Trial: Pfizer Executive
There were no cases of severe allergic reactions to Pfizer Inc and partner BioNTech SE's COVID-19 vaccine candidate during clinical trials, a Pfizer executive said at a regulatory conference on Friday
-
When And How Will COVID-19 Vaccines Become Available Around The World
Pfizer Inc with partner BioNTech SE and Moderna Inc have released trial data showing their COVID-19 vaccines to be about 95 per cent effective at preventing the illness, while AstraZeneca Plc this week said its vaccine could be up to 90 per cent effective.
-
Why Pfizer Covid Vaccine May Not Be Available At Pharmacies Any Time Soon
Work to distribute the experimental COVID-19 vaccine developed by Pfizer Inc and BioNTech SE is gearing up after the companies announced successful interim data earlier on Monday, but it will not be coming to local pharmacies for the general public any time soon.
-
Gold Plunges 5% As Stocks Soar On Covid-19 Vaccine Euphoria
Pfizer Inc said its experimental COVID-19 vaccine was more than 90 per cent effective; Pfizer and BioNTech SE said they expect to seek U.S. emergency use authorization later this month.
-
What To Know About COVID-19 Vaccine For US Children
The US Food and Drug Administration is considering authorizing a COVID-19 vaccine for children aged 5 to 11. The vaccine from Pfizer Inc and BioNTech SE has been available in the United States to kids aged 12 to 15 since May.
-
Pfizer Submits Initial Data For Covid Vaccine Booster Authorization
Pfizer Inc and its German partner BioNTech SE have submitted to U.S. regulators the initial data from an early-stage trial toward seeking authorization of a booster dose of their COVID-19 vaccine, the drugmakers said on Monday.
-
Pfizer, Moderna Vaccines Highly Effective Even After 1st Shot: US Study
COVID-19 vaccines developed by Pfizer Inc with BioNTech SE and Moderna Inc reduced the risk of infection by 80 per cent two weeks or more after the first of two shots, according to data from a real-world study of vaccinated US healthcare personnel and first responders released on Monday.
-
Pfizer, BioNTech Launch COVID-19 Vaccine Trial In Children Under 12
Pfizer Inc and German partner BioNTech SE began testing their COVID-19 vaccine in children under 12, with hopes of expanding vaccination to that age range by early 2022, the U.S. drugmaker said on Thursday.
-
Pfizer-Biontech Testing Booster Of Their COVID-19 Vaccine In New Trial
Pfizer Inc and BioNTech SE said on Thursday they are testing a third dose of their COVID-19 vaccine to better understand the immune response against new variants of the virus.
-
South African Virus Variant Could Significantly Reduce Vaccine Protection: Pfizer
A laboratory study suggests that the South African variant of the coronavirus may reduce antibody protection from the Pfizer Inc/BioNTech SE vaccine by two-thirds, and it is not clear if the shot will be effective against the mutation, the companies said on Wednesday.
-
Pfizer And BioNtech To Offer Covid Vaccine To Volunteers Who Got Placebo
Pfizer Inc and its partner BioNTech Se plan to give volunteers who received a placebo in its COVID-19 vaccine trial an option to receive a first dose of the vaccine by March 1, 2021, while staying within the study.
-
How Moderna's COVID-19 Vaccine Compares To That Of Pfizer's
US regulators authorized Moderna Inc's COVID-19 vaccine for emergency use on Friday, a week after granting the first US authorization to Pfizer Inc and BioNTech SE's coronavirus shot.
-
US Drug Regulator Investigating 5 Allergic Reactions After Pfizer Shot
The US Food and Drug Administration is investigating around five allergic reactions that happened after people were administered Pfizer Inc and BioNTech SE's COVID-19 vaccine in the United States this week, a top FDA official said late on Friday.
-
BioNTech CEO Reveals "Biggest Challenge" After Covid Vaccine Gets US Nod
The chief executive of Germany's BioNTech SE said the biggest challenge facing it and partner Pfizer Inc now that their COVID-19 vaccine is authorized for use in the United States will be to scale up manufacturing to meet huge demand.
-
No Allergic Reactions Recorded During Covid Vaccine Trial: Pfizer Executive
There were no cases of severe allergic reactions to Pfizer Inc and partner BioNTech SE's COVID-19 vaccine candidate during clinical trials, a Pfizer executive said at a regulatory conference on Friday
-
When And How Will COVID-19 Vaccines Become Available Around The World
Pfizer Inc with partner BioNTech SE and Moderna Inc have released trial data showing their COVID-19 vaccines to be about 95 per cent effective at preventing the illness, while AstraZeneca Plc this week said its vaccine could be up to 90 per cent effective.
-
Why Pfizer Covid Vaccine May Not Be Available At Pharmacies Any Time Soon
Work to distribute the experimental COVID-19 vaccine developed by Pfizer Inc and BioNTech SE is gearing up after the companies announced successful interim data earlier on Monday, but it will not be coming to local pharmacies for the general public any time soon.
-
Gold Plunges 5% As Stocks Soar On Covid-19 Vaccine Euphoria
Pfizer Inc said its experimental COVID-19 vaccine was more than 90 per cent effective; Pfizer and BioNTech SE said they expect to seek U.S. emergency use authorization later this month.
